Overview

* Standard BioTools Q3 2025 revenue falls 11% yr/yr, reflecting declines in consumables and services

* Adjusted EBITDA for Q3 2025 missed analyst expectations

* Company implemented restructuring plan for $40 mln annualized cost savings

Outlook

* Company expects positive adjusted EBITDA in 2026

* Standard BioTools ( LAB ) anticipates $550 mln cash from Illumina transaction in 2026

* Company maintains 2025 revenue guidance of $165 mln to $175 mln

Result Drivers

* RESTRUCTURING PLAN - Co implemented restructuring plan for $40 mln annualized cost savings, including 20% workforce reduction

* CONSUMABLES REVENUE DECLINE - Decline in consumables revenue due to reduced project funding in flow and microfluidics, partially offset by imaging growth

* SERVICES REVENUE DECREASE - Services revenue decreased due to fewer active service contracts and improved instrument quality, reducing on-demand revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $19.60

Revenue mln

Q3 EPS -$0.09

Q3 Net -$34.68

Income mln

Q3 Miss -$16.50 -$11.10

Adjusted mln mln (3

EBITDA Analysts

)

Q3 Gross 48.50%

Margin

Q3 53.50%

Adjusted

Gross

Margin

Q3 -$32.90

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Standard BioTools Inc ( LAB ) is $1.78, about 30.1% above its November 3 closing price of $1.24

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)